ENANTA PHARMACEUTICALS INC — Form 10-K
Filed November 18, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 2/100
What the filing says
Enanta Pharmaceuticals disclosed its subsidiary structure (Enanta Pharmaceuticals Security Corporation, Massachusetts-incorporated) and PricewaterhouseCoopers LLP provided standard consent to incorporate its audit report by reference into existing S-3 and S-8 registration statements. No financial, operational, or strategic changes disclosed.
Why this rating
Standard boilerplate exhibits required in every 10-K; subsidiary and audit consent are administrative formalities with zero material business impact.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.